Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
Pre-Tax Income
Verona Pharma PLC
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Verona Pharma PLC
NASDAQ:VRNA
|
Pre-Tax Income
-$53.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Pre-Tax Income
£5.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Pre-Tax Income
$7.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
11%
|
|
Indivior PLC
LSE:INDV
|
Pre-Tax Income
$6m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Pre-Tax Income
$281m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Pre-Tax Income
-£36.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Verona Pharma PLC's Pre-Tax Income?
Pre-Tax Income
-53.9m
USD
Based on the financial report for Dec 31, 2023, Verona Pharma PLC's Pre-Tax Income amounts to -53.9m USD.
What is Verona Pharma PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-11%
Over the last year, the Pre-Tax Income growth was 21%. The average annual Pre-Tax Income growth rates for Verona Pharma PLC have been 6% over the past three years , -11% over the past five years .